Cargando…

Recommendations on the Proper Use of SGLT2 Inhibitors

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Special Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944824/ https://www.ncbi.nlm.nih.gov/pubmed/31729165 http://dx.doi.org/10.1111/jdi.13160

Ejemplares similares

Proper Management of People with Obesity during the COVID-19 Pandemic
por: Lim, Soo, et al.
Publicado: (2020)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
por: De La Flor, José C., et al.
Publicado: (2023)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

COPD in China: The Burden and Importance of Proper Management
por: Fang, Xiaocong, et al.
Publicado: (2011)

Role of narrative-based medicine in proper patient assessment
por: Rosti, Giovanni
Publicado: (2017)

Is It Proper for Consumptives to Marry?
por: Hartsen, F. A.
Publicado: (1871)

Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
por: Sheu, Wayne Huey-Herng, et al.
Publicado: (2020)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: Bobrowski, David, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
por: Kellon, Eleanor M., et al.
Publicado: (2023)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations
por: Maffei, Pietro, et al.
Publicado: (2023)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Teaching transfusion medicine: current situation and proposals for proper medical training
por: Flausino, Gustavo de Freitas, et al.
Publicado: (2015)

The Proper Relation of the Superintendent to the Trustees of a Hospital
por: Hurd, Henry M.
Publicado: (1911)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Falls and SGLT-2 inhibitors in geriatric patients—A case report
por: Taşdemir, Anil, et al.
Publicado: (2020)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
por: Iqbal, Qasim Zafar, et al.
Publicado: (2020)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
por: Chua, Marvin Wei Jie
Publicado: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

SGLT2 Inhibitors: the Gift that Keeps on Giving
por: Garcia, Maria Victoria Faith, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023)

Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials
por: Hosono, Makoto, et al.
Publicado: (2019)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e3gm59easc34cdrh7t7j5tedq4